Author: Derek G. Waller
Publisher: Elsevier Health Sciences
ISBN: 0702055034
Category : Medical
Languages : en
Pages : 741
Book Description
This book covers all the pharmacology you need, from basic science pharmacology and pathophysiology, through to clinical pharmacology to therapeutics, in line with the integrated approach of new medical curricula. The first section covers the basic principles, and the rest is organised by body systems. The book ends with sections on toxicity and prescribing practice. Integrates basic science pharmacology, clinical pharmacology and therapeutics Brief review of pathophysiology of major diseases Case histories and multiple choice questions (and answers) Tabular presentation of all common drugs within each class Section on further reading Kinetics chapter simplified with more practical examples Includes more on genetic issues Drug tables made more concise to make information more accessible Fully updated to reflect current clinical practice
Medical Pharmacology and Therapeutics E-Book
Author: Derek G. Waller
Publisher: Elsevier Health Sciences
ISBN: 0702055034
Category : Medical
Languages : en
Pages : 741
Book Description
This book covers all the pharmacology you need, from basic science pharmacology and pathophysiology, through to clinical pharmacology to therapeutics, in line with the integrated approach of new medical curricula. The first section covers the basic principles, and the rest is organised by body systems. The book ends with sections on toxicity and prescribing practice. Integrates basic science pharmacology, clinical pharmacology and therapeutics Brief review of pathophysiology of major diseases Case histories and multiple choice questions (and answers) Tabular presentation of all common drugs within each class Section on further reading Kinetics chapter simplified with more practical examples Includes more on genetic issues Drug tables made more concise to make information more accessible Fully updated to reflect current clinical practice
Publisher: Elsevier Health Sciences
ISBN: 0702055034
Category : Medical
Languages : en
Pages : 741
Book Description
This book covers all the pharmacology you need, from basic science pharmacology and pathophysiology, through to clinical pharmacology to therapeutics, in line with the integrated approach of new medical curricula. The first section covers the basic principles, and the rest is organised by body systems. The book ends with sections on toxicity and prescribing practice. Integrates basic science pharmacology, clinical pharmacology and therapeutics Brief review of pathophysiology of major diseases Case histories and multiple choice questions (and answers) Tabular presentation of all common drugs within each class Section on further reading Kinetics chapter simplified with more practical examples Includes more on genetic issues Drug tables made more concise to make information more accessible Fully updated to reflect current clinical practice
Disease Management
Author: Michael D. Randall
Publisher:
ISBN: 9780857112095
Category : Medical
Languages : en
Pages : 0
Book Description
This clinical pharmacy textbook puts pharmacology into practice using an holistic approach to the management, treatment and monitoring of various diseases.
Publisher:
ISBN: 9780857112095
Category : Medical
Languages : en
Pages : 0
Book Description
This clinical pharmacy textbook puts pharmacology into practice using an holistic approach to the management, treatment and monitoring of various diseases.
Drug Metabolism in Diseases
Author: Wen Xie
Publisher: Academic Press
ISBN: 0128029633
Category : Medical
Languages : en
Pages : 296
Book Description
Drug Metabolism in Diseases is a comprehensive reference devoted to the current state of research on the impact of various disease states on drug metabolism. The book contains valuable insights into mechanistic effects and examples of how to accurately predict drug metabolism during these different pathophysiological states. Each chapter clearly presents the effects of changes in drug metabolism and drug transporters on pharmacokinetics and disposition. This is a unique and useful approach for all those involved in drug discovery and development, and for clinicians and researchers in drug metabolism, pharmacology, and clinical pharmacology. - Written and edited by leaders in drug metabolism from academia and industry - Covers important topics, such as pharmacogenomics, drug metabolism in transplant patients, xenobiotic receptors, drug metabolism in geriatric and pediatric populations, and more - Highlights topics of importance in drug discovery and development, and for safe and effective drug use in the clinic
Publisher: Academic Press
ISBN: 0128029633
Category : Medical
Languages : en
Pages : 296
Book Description
Drug Metabolism in Diseases is a comprehensive reference devoted to the current state of research on the impact of various disease states on drug metabolism. The book contains valuable insights into mechanistic effects and examples of how to accurately predict drug metabolism during these different pathophysiological states. Each chapter clearly presents the effects of changes in drug metabolism and drug transporters on pharmacokinetics and disposition. This is a unique and useful approach for all those involved in drug discovery and development, and for clinicians and researchers in drug metabolism, pharmacology, and clinical pharmacology. - Written and edited by leaders in drug metabolism from academia and industry - Covers important topics, such as pharmacogenomics, drug metabolism in transplant patients, xenobiotic receptors, drug metabolism in geriatric and pediatric populations, and more - Highlights topics of importance in drug discovery and development, and for safe and effective drug use in the clinic
Pharmacology and Nutritional Intervention in the Treatment of Disease
Author: Faik Atroshi
Publisher: BoD – Books on Demand
ISBN: 9535113836
Category : Medical
Languages : en
Pages : 430
Book Description
Pharmacology and Nutritional Intervention in the Treatment of Disease is a book dealing with an important research field that has worldwide significance. Its aim is to strengthen the research base of this field of investigation as it yields knowledge that has important implications for biomedicine, public health and biotechnology. The book has brought together an interdisciplinary group of contributors and prominent scholars from different parts of the world. The basic purpose of this book was to promote interaction and discussion of problems of mutual interests among people in related fields everywhere. The main subjects of the book include nutrition, mechanisms underlying treatments, physiological aspects of vitamins and trace elements, antioxidants: regulation, signalling, infection and inflammation, and degenerative and chronic diseases.
Publisher: BoD – Books on Demand
ISBN: 9535113836
Category : Medical
Languages : en
Pages : 430
Book Description
Pharmacology and Nutritional Intervention in the Treatment of Disease is a book dealing with an important research field that has worldwide significance. Its aim is to strengthen the research base of this field of investigation as it yields knowledge that has important implications for biomedicine, public health and biotechnology. The book has brought together an interdisciplinary group of contributors and prominent scholars from different parts of the world. The basic purpose of this book was to promote interaction and discussion of problems of mutual interests among people in related fields everywhere. The main subjects of the book include nutrition, mechanisms underlying treatments, physiological aspects of vitamins and trace elements, antioxidants: regulation, signalling, infection and inflammation, and degenerative and chronic diseases.
Levodopa pharmacokinetics -from stomach to brain
Author: Maria Nord
Publisher: Linköping University Electronic Press
ISBN: 9176855570
Category :
Languages : sv
Pages : 81
Book Description
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders and it is caused by a loss of dopamine (DA) producing neurons in the basal ganglia in the brain. The PD patient suffers from motor symptoms such as tremor, bradykinesia and rigidity and treatment with levodopa (LD), the precursor of DA, has positive effects on these symptoms. Several factors affect the availability of orally given LD. Gastric emptying (GE) is one factor and it has been shown to be delayed in PD patients resulting in impaired levodopa uptake. Different enzymes metabolize LD on its way from the gut to the brain resulting in less LD available in the brain and more side effects from the metabolites. By adding dopa decarboxylase inhibitors (carbidopa or benserazide) or COMT-inhibitors (e.g. entacapone) the bioavailability of LD increases significantly and more LD can pass the blood-brain-barrier and be converted to DA in the brain. It has been considered of importance to avoid high levodopa peaks in the brain because this seems to induce changes in postsynaptic dopaminergic neurons causing disabling motor complications in PD patients. More continuously given LD, e.g. duodenal or intravenous (IV) infusions, has been shown to improve these motor complications. Deep brain stimulation of the subthalamic nucleus (STN DBS) has also been proven to improve motor complications and to make it possible to reduce the LD dosage in PD patients. In this doctoral thesis the main purpose is to study the pharmacokinetics of LD in patients with PD and motor complications; in blood and subcutaneous tissue and study the effect of GE and PD stage on LD uptake and the effect of continuously given LD (CDS) on LD uptake and GE; in blood and cerebrospinal fluid (CSF) when adding the peripheral enzyme inhibitors entacapone and carbidopa to LD infusion IV; in brain during STN DBSand during oral or IV LD treatment. To conclude, LD uptake is more favorable in PD patients with less severe disease and GE is delayed in PD patients. No obvious relation between LD uptake and GE or between GE and PD stage is seen and CDS decreases the LD levels. Entacapone increases the maximal concentration of LD in blood and CSF. This is more evident with additional carbidopa and important to consider in avoiding high LD peaks in brain during PD treatment. LD in brain increases during both oral and IV LD treatment and the DA levels follows LD well indicating that PD patients still have capacity to metabolize LD to DA despite probable pronounced nigral degeneration. STN DBS seems to increase putaminal DA levels and together with IV LD treatment also increases LD in brain possibly explaining why it is possible to decrease LD medication after STN DBS surgery. Parkinsons sjukdom (PS) är en av de vanligaste s.k. neurodegenerativasjukdomarna och orsakas av förlust av dopamin(DA)producerande nervceller i hjärnan. Detta orsakar motoriska symptom såsom skakningar, stelhet och förlångsammade rörelser. Levodopa (LD) är ett ämne, som kan omvandlas till DA i hjärnan och ge symptomlindring och det är oftast förstahandsval vid behandling av patienter med PS. Flera faktorer påverkar tillgängligheten av LD, bl.a. den hastighet som magsäcken tömmer sig med och denna verkar förlångsammad hos personer med PS vilket ger sämre tillgänglighet av LD i blodet och därmed i hjärnan. LD bryts även ner i hög grad av olika enzym ute i kroppen vilket leder till mindre mängd LD som hamnar i hjärnan och till fler nedbrytningsprodukter som orsakar biverkningar. Tillägg av enzymhämmare leder till ökad mängd LD som kan nå hjärnan och omvandlas till DA. Det anses viktigt att undvika höga toppar av LD i hjärnan då dessa verkar bidra till utvecklandet av besvärliga motoriska komplikationer hos patienter med PS. Om LD ges mer kontinuerligt, exempelvis som en kontinuerlig infusion in i tarmen eller i blodet, så minskar dessa motoriska komplikationer. Inopererande av stimulatorer i vissa delar av hjärnan (DBS) har också visat sig minska dessa motoriska komplikationer och även resultera i att man kan minska LD-dosen. Huvudsyftet med den här avhandlingen är att studera LD hos patienter med PS; i blod och fettvävnad då LD ges i tablettform och se om det finns något samband med LD-upptag och hastigheten på magsäckstömningen (MT) och om kontinuerligt given LD påverkar LD-upptaget eller MT; i blod och i ryggmärgsvätska då enzymhämmarna entakapon och karbidopa tillsätts LD; i hjärna vid behandling med DBS och då LD ges både som tablett och som infusion i blodet. Sammanfattningsvis kan vi se att LD-upptaget är mer gynnsamt hos patienter med PS i tidigare skede av sjukdomens komplikationsfas. MT är förlångsammad hos patienter med PS och det är inget tydligt samband mellan LD-upptag och MT eller mellan MT och sjukdomsgrad. Kontinuerligt given LD minskar LDnivåerna. Enzymhämmaren entakapon ökar den maximala koncentrationen av LD i blod och ryggmärgsvätska och effekten är mer tydlig vid tillägg av karbidopa vilket är viktigt att ta i beaktande vid behandling av PS för att undvika höga toppar av LD i hjärnan. LD ökar i hjärnan då man behandlar med LD i tablettform och som infusion i blodet och DA-nivåerna i hjärnan följer LD väl vilket visar på att patienter med PS fortfarande kan omvandla LD till DA trots trolig uttalad brist av de DA-producerande nervcellerna i hjärnan. DBS verkar öka DA i vissa områden i hjärnan och tillsammans med LD-infusion i blodet verkar det även öka LD i hjärnan och det kan förklara varför man kan sänka LDdosen efter DBS-operation.
Publisher: Linköping University Electronic Press
ISBN: 9176855570
Category :
Languages : sv
Pages : 81
Book Description
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders and it is caused by a loss of dopamine (DA) producing neurons in the basal ganglia in the brain. The PD patient suffers from motor symptoms such as tremor, bradykinesia and rigidity and treatment with levodopa (LD), the precursor of DA, has positive effects on these symptoms. Several factors affect the availability of orally given LD. Gastric emptying (GE) is one factor and it has been shown to be delayed in PD patients resulting in impaired levodopa uptake. Different enzymes metabolize LD on its way from the gut to the brain resulting in less LD available in the brain and more side effects from the metabolites. By adding dopa decarboxylase inhibitors (carbidopa or benserazide) or COMT-inhibitors (e.g. entacapone) the bioavailability of LD increases significantly and more LD can pass the blood-brain-barrier and be converted to DA in the brain. It has been considered of importance to avoid high levodopa peaks in the brain because this seems to induce changes in postsynaptic dopaminergic neurons causing disabling motor complications in PD patients. More continuously given LD, e.g. duodenal or intravenous (IV) infusions, has been shown to improve these motor complications. Deep brain stimulation of the subthalamic nucleus (STN DBS) has also been proven to improve motor complications and to make it possible to reduce the LD dosage in PD patients. In this doctoral thesis the main purpose is to study the pharmacokinetics of LD in patients with PD and motor complications; in blood and subcutaneous tissue and study the effect of GE and PD stage on LD uptake and the effect of continuously given LD (CDS) on LD uptake and GE; in blood and cerebrospinal fluid (CSF) when adding the peripheral enzyme inhibitors entacapone and carbidopa to LD infusion IV; in brain during STN DBSand during oral or IV LD treatment. To conclude, LD uptake is more favorable in PD patients with less severe disease and GE is delayed in PD patients. No obvious relation between LD uptake and GE or between GE and PD stage is seen and CDS decreases the LD levels. Entacapone increases the maximal concentration of LD in blood and CSF. This is more evident with additional carbidopa and important to consider in avoiding high LD peaks in brain during PD treatment. LD in brain increases during both oral and IV LD treatment and the DA levels follows LD well indicating that PD patients still have capacity to metabolize LD to DA despite probable pronounced nigral degeneration. STN DBS seems to increase putaminal DA levels and together with IV LD treatment also increases LD in brain possibly explaining why it is possible to decrease LD medication after STN DBS surgery. Parkinsons sjukdom (PS) är en av de vanligaste s.k. neurodegenerativasjukdomarna och orsakas av förlust av dopamin(DA)producerande nervceller i hjärnan. Detta orsakar motoriska symptom såsom skakningar, stelhet och förlångsammade rörelser. Levodopa (LD) är ett ämne, som kan omvandlas till DA i hjärnan och ge symptomlindring och det är oftast förstahandsval vid behandling av patienter med PS. Flera faktorer påverkar tillgängligheten av LD, bl.a. den hastighet som magsäcken tömmer sig med och denna verkar förlångsammad hos personer med PS vilket ger sämre tillgänglighet av LD i blodet och därmed i hjärnan. LD bryts även ner i hög grad av olika enzym ute i kroppen vilket leder till mindre mängd LD som hamnar i hjärnan och till fler nedbrytningsprodukter som orsakar biverkningar. Tillägg av enzymhämmare leder till ökad mängd LD som kan nå hjärnan och omvandlas till DA. Det anses viktigt att undvika höga toppar av LD i hjärnan då dessa verkar bidra till utvecklandet av besvärliga motoriska komplikationer hos patienter med PS. Om LD ges mer kontinuerligt, exempelvis som en kontinuerlig infusion in i tarmen eller i blodet, så minskar dessa motoriska komplikationer. Inopererande av stimulatorer i vissa delar av hjärnan (DBS) har också visat sig minska dessa motoriska komplikationer och även resultera i att man kan minska LD-dosen. Huvudsyftet med den här avhandlingen är att studera LD hos patienter med PS; i blod och fettvävnad då LD ges i tablettform och se om det finns något samband med LD-upptag och hastigheten på magsäckstömningen (MT) och om kontinuerligt given LD påverkar LD-upptaget eller MT; i blod och i ryggmärgsvätska då enzymhämmarna entakapon och karbidopa tillsätts LD; i hjärna vid behandling med DBS och då LD ges både som tablett och som infusion i blodet. Sammanfattningsvis kan vi se att LD-upptaget är mer gynnsamt hos patienter med PS i tidigare skede av sjukdomens komplikationsfas. MT är förlångsammad hos patienter med PS och det är inget tydligt samband mellan LD-upptag och MT eller mellan MT och sjukdomsgrad. Kontinuerligt given LD minskar LDnivåerna. Enzymhämmaren entakapon ökar den maximala koncentrationen av LD i blod och ryggmärgsvätska och effekten är mer tydlig vid tillägg av karbidopa vilket är viktigt att ta i beaktande vid behandling av PS för att undvika höga toppar av LD i hjärnan. LD ökar i hjärnan då man behandlar med LD i tablettform och som infusion i blodet och DA-nivåerna i hjärnan följer LD väl vilket visar på att patienter med PS fortfarande kan omvandla LD till DA trots trolig uttalad brist av de DA-producerande nervcellerna i hjärnan. DBS verkar öka DA i vissa områden i hjärnan och tillsammans med LD-infusion i blodet verkar det även öka LD i hjärnan och det kan förklara varför man kan sänka LDdosen efter DBS-operation.
What You Need to Know about Infectious Disease
Author: Madeline Drexler
Publisher:
ISBN:
Category :
Languages : en
Pages :
Book Description
Publisher:
ISBN:
Category :
Languages : en
Pages :
Book Description
Drug Benefits and Risks
Author: Chris J. van Boxtel
Publisher: John Wiley & Sons
ISBN: 9780471899273
Category : Medical
Languages : en
Pages : 738
Book Description
This is an inclusive reference exploring the scientific basis and practice of drug therapy. The key concept is to look at the balance between the benefits and risks of drugs but in this context also the social impact which drugs have in modern societies is highlighted. Taking an evidence-based approach to the problem, the practice of clinical pharmacology and pharmacotherapy in the developing as well as the developed world is examined. For this purpose the book * Covers general clinical pharmacology, pharmacology of various drug groups and the treatments specific to various diseases * Gives guidance on how doctors should act so that drugs can be used effectively and safely * Encourages the rational use of drugs in society This book brings together a large amount of excellent content that will be invaluable for anyone working within, or associated with, the field of clinical pharmacology and pharmacotherapy - undergraduates, postgraduates, regulatory authorities and the pharmaceutical industry.
Publisher: John Wiley & Sons
ISBN: 9780471899273
Category : Medical
Languages : en
Pages : 738
Book Description
This is an inclusive reference exploring the scientific basis and practice of drug therapy. The key concept is to look at the balance between the benefits and risks of drugs but in this context also the social impact which drugs have in modern societies is highlighted. Taking an evidence-based approach to the problem, the practice of clinical pharmacology and pharmacotherapy in the developing as well as the developed world is examined. For this purpose the book * Covers general clinical pharmacology, pharmacology of various drug groups and the treatments specific to various diseases * Gives guidance on how doctors should act so that drugs can be used effectively and safely * Encourages the rational use of drugs in society This book brings together a large amount of excellent content that will be invaluable for anyone working within, or associated with, the field of clinical pharmacology and pharmacotherapy - undergraduates, postgraduates, regulatory authorities and the pharmaceutical industry.
Basic and Clinical Pharmacology 15e
Author: Bertram G. Katzung
Publisher: McGraw Hill Professional
ISBN: 1260452328
Category : Medical
Languages : en
Pages : 1326
Book Description
Master key pharmacological concepts and practices with the most comprehensive, authoritative guide available Doody's Core Titles for 2023! Presented in full-color and packed with hundreds of illustrations, Basic and Clinical Pharmacology is the wide-ranging, engaging guide students have counted on for decades. Organized to reflect the course sequence in many pharmacology courses and in integrated curricula, the guide covers the important concepts students need to know about the science of pharmacology and its application to clinical practice. This edition has been extensively updated to provide expanded coverage of transporters, pharmacogenomics, and new drugs Delivers the knowledge and insight needed to excel in every facet of pharmacology!. Encompasses all aspects of medical pharmacology, including botanicals and over-the-counter drugs Major revisions of the chapters on immunopharmacology, antiseizure, antipsychotic, antidepressant, antidiabetic, anti-inflammatory, and antiviral drugs, prostaglandins, and central nervous system neurotransmitters New chapter on the increasingly relevant topic of cannabis pharmacology Each chapter opens with a case study, covers drug groups and prototypes, and closes with summary tables and diagrams that encapsulate important information Revised full-color illustrations provide more information about drug mechanisms and effects and help clarify important concepts Trade Name/Generic Name tables are provided at end of each chapter for easy reference when writing a chart order or prescription Includes descriptions of important new drugs released through May 2019 New and updated coverage of general concepts relating to recently discovered receptors, receptor mechanisms, and drug transporters
Publisher: McGraw Hill Professional
ISBN: 1260452328
Category : Medical
Languages : en
Pages : 1326
Book Description
Master key pharmacological concepts and practices with the most comprehensive, authoritative guide available Doody's Core Titles for 2023! Presented in full-color and packed with hundreds of illustrations, Basic and Clinical Pharmacology is the wide-ranging, engaging guide students have counted on for decades. Organized to reflect the course sequence in many pharmacology courses and in integrated curricula, the guide covers the important concepts students need to know about the science of pharmacology and its application to clinical practice. This edition has been extensively updated to provide expanded coverage of transporters, pharmacogenomics, and new drugs Delivers the knowledge and insight needed to excel in every facet of pharmacology!. Encompasses all aspects of medical pharmacology, including botanicals and over-the-counter drugs Major revisions of the chapters on immunopharmacology, antiseizure, antipsychotic, antidepressant, antidiabetic, anti-inflammatory, and antiviral drugs, prostaglandins, and central nervous system neurotransmitters New chapter on the increasingly relevant topic of cannabis pharmacology Each chapter opens with a case study, covers drug groups and prototypes, and closes with summary tables and diagrams that encapsulate important information Revised full-color illustrations provide more information about drug mechanisms and effects and help clarify important concepts Trade Name/Generic Name tables are provided at end of each chapter for easy reference when writing a chart order or prescription Includes descriptions of important new drugs released through May 2019 New and updated coverage of general concepts relating to recently discovered receptors, receptor mechanisms, and drug transporters
Small Animal Clinical Pharmacology E-Book
Author: Jill E. Maddison
Publisher: Elsevier Health Sciences
ISBN: 0702037257
Category : Medical
Languages : en
Pages : 600
Book Description
The eBook version of this title gives you access to the complete book content electronically*. Evolve eBooks allows you to quickly search the entire book, make notes, add highlights, and study more efficiently. Buying other Evolve eBooks titles makes your learning experience even better: all of the eBooks will work together on your electronic "bookshelf", so that you can search across your entire library of Veterinary Medicine eBooks. *Please note that this version is the eBook only and does not include the printed textbook. Alternatively, you can buy the Text and Evolve eBooks Package (which gives you the printed book plus the eBook). Please scroll down to our Related Titles section to find this title. Small Animal Clinical Pharmacology is a practical, clinically-oriented pharmacology text designed to provide the veterinary student and practitioner with all the relevant information needed when designing drug treatment regimens for pets in small animal veterinary practice. Comprehensively updated and revised, the second edition of this core text covers essential new information on drugs used in the management of a range of presenting conditions including heart disease and cardiac arrhythmias. For the second edition new authors, superb new illustrations and a second colour have all been introduced. With its unique approach combining a thorough understanding of the pharmacological action of drugs with a basic understanding of the relevant physiology and pathophysiology of systems and tissues affected, Small Animal Clinical Pharmacology continues to be an indispensable book for all veterinary students and practitioners. - Organised by drug class in a uniform and detailed structure which means it is easy to locate key information on dose rates, routes of administration, drug interactions and special considerations at a glance - Key chapters based around treatment of disorders of particular body systems, eg cardiovascular and thyroid disorders - Essential introductory chapters covering pharmacokinetics, general pharmacological principles and adverse reactions for a thorough basic grounding in the subject - All authors are experienced clinicians and recognised experts in their field who bring a down to earth and practical approach to the text
Publisher: Elsevier Health Sciences
ISBN: 0702037257
Category : Medical
Languages : en
Pages : 600
Book Description
The eBook version of this title gives you access to the complete book content electronically*. Evolve eBooks allows you to quickly search the entire book, make notes, add highlights, and study more efficiently. Buying other Evolve eBooks titles makes your learning experience even better: all of the eBooks will work together on your electronic "bookshelf", so that you can search across your entire library of Veterinary Medicine eBooks. *Please note that this version is the eBook only and does not include the printed textbook. Alternatively, you can buy the Text and Evolve eBooks Package (which gives you the printed book plus the eBook). Please scroll down to our Related Titles section to find this title. Small Animal Clinical Pharmacology is a practical, clinically-oriented pharmacology text designed to provide the veterinary student and practitioner with all the relevant information needed when designing drug treatment regimens for pets in small animal veterinary practice. Comprehensively updated and revised, the second edition of this core text covers essential new information on drugs used in the management of a range of presenting conditions including heart disease and cardiac arrhythmias. For the second edition new authors, superb new illustrations and a second colour have all been introduced. With its unique approach combining a thorough understanding of the pharmacological action of drugs with a basic understanding of the relevant physiology and pathophysiology of systems and tissues affected, Small Animal Clinical Pharmacology continues to be an indispensable book for all veterinary students and practitioners. - Organised by drug class in a uniform and detailed structure which means it is easy to locate key information on dose rates, routes of administration, drug interactions and special considerations at a glance - Key chapters based around treatment of disorders of particular body systems, eg cardiovascular and thyroid disorders - Essential introductory chapters covering pharmacokinetics, general pharmacological principles and adverse reactions for a thorough basic grounding in the subject - All authors are experienced clinicians and recognised experts in their field who bring a down to earth and practical approach to the text
Infectious Disease and Pharmacology
Author: William Benitz
Publisher: Elsevier Health Sciences
ISBN: 0323568564
Category : Medical
Languages : en
Pages : 329
Book Description
Dr. Richard Polin's Neonatology Questions and Controversies series highlights the most challenging aspects of neonatal care, offering trustworthy guidance on up-to-date diagnostic and treatment options in the field. In each volume, renowned experts address the clinical problems of greatest concern to today's practitioners, helping you handle difficult practice issues and provide optimal, evidence-based care to every patient. - Stay fully up to date in this fast-changing field with Infectious Disease and Pharmacology, an all-new volume in the series. - Thorough, up-to-date content on the epidemiology, clinical manifestations, treatment, and outcomes for neonatal-perinatal infections, including necrotizing enterocolitis, neonatal HSV, and congenital Zika virus infection. - The latest information on dosing of antibiotics, antivirals, and antifungals. - Current coverage of therapies for neonatal gastroesophageal reflux, seizures, neuroprotection, and neonatal abstinence syndrome, as well as pharmacokinetic and pharmacogenetic considerations in neonatal care. - Consistent chapter organization to help you find information quickly and easily. - The most authoritative advice available from world-class neonatologists who share their knowledge of new trends and developments in neonatal care. Purchase each volume individually, or get the entire 7-volume set!Gastroenterology and NutritionHematology, Immunology and GeneticsHemodynamics and CardiologyInfectious Disease and Pharmacology New Volume!Nephrology and Fluid/Electrolyte PhysiologyNeurologyThe Newborn Lung
Publisher: Elsevier Health Sciences
ISBN: 0323568564
Category : Medical
Languages : en
Pages : 329
Book Description
Dr. Richard Polin's Neonatology Questions and Controversies series highlights the most challenging aspects of neonatal care, offering trustworthy guidance on up-to-date diagnostic and treatment options in the field. In each volume, renowned experts address the clinical problems of greatest concern to today's practitioners, helping you handle difficult practice issues and provide optimal, evidence-based care to every patient. - Stay fully up to date in this fast-changing field with Infectious Disease and Pharmacology, an all-new volume in the series. - Thorough, up-to-date content on the epidemiology, clinical manifestations, treatment, and outcomes for neonatal-perinatal infections, including necrotizing enterocolitis, neonatal HSV, and congenital Zika virus infection. - The latest information on dosing of antibiotics, antivirals, and antifungals. - Current coverage of therapies for neonatal gastroesophageal reflux, seizures, neuroprotection, and neonatal abstinence syndrome, as well as pharmacokinetic and pharmacogenetic considerations in neonatal care. - Consistent chapter organization to help you find information quickly and easily. - The most authoritative advice available from world-class neonatologists who share their knowledge of new trends and developments in neonatal care. Purchase each volume individually, or get the entire 7-volume set!Gastroenterology and NutritionHematology, Immunology and GeneticsHemodynamics and CardiologyInfectious Disease and Pharmacology New Volume!Nephrology and Fluid/Electrolyte PhysiologyNeurologyThe Newborn Lung